Abstract-The purpose of this opinion is to present a case for targeting sphingosine kinase 2 (SK2) in autoimmune/inflammatory disease. Data obtained using Sphk2
-/-mice suggests that SK2 is an anti-inflammatory enzyme, although this might be misleading because of a compensatory increase in expression of a second isoform, sphingosine kinase 1 (SK1), which functions as a pro-inflammatory enzyme. SK2 is involved in regulating interleukin-12/interferon- and histone deacetylase-1/2 signalling and potentially retinoid related orphan receptor-t stability linked with Th17 cell polarisation. Therefore, there is a need to develop highly potent SK2 inhibitors with selectivity over SK1 to clearly define the role of SK2 in autoimmune/inflammatory disease. Structural determinants of SK2 relative to SK1 will enable design of selective SK2 inhibitors.
Sphingosine 1-phosphate Signalling
The bioactive lipid, sphingosine 1-phosphate (S1P) is formed by the phosphorylation of sphingosine and this reaction is catalysed by two isoforms of sphingosine kinase, termed SK1
and SK2. These enzymes are encoded by different genes and are localised in distinct subcellular compartments. The enzymes also exhibit distinct biochemical properties and inhibitor sensitivities [1] . S1P is degraded by S1P lyase to produce (E)-2-hexadecenal and phosphoethanolamine and is dephosphorylated by S1P phosphatase to reform sphingosine [1] . S1P is released from cells using specific transporters (e.g. Spns2) (see Glossary) in the plasma membrane and binds to a family of G protein-coupled receptors (GPCR), the S1P receptors (S1P 1 -S1P 5 ) [2, 3] on cells to induce biological responses. Intracellular S1P formed by SK2 can bind to various targets, such as histone deacetylase 1/2 (HDAC-1/2) [4] , human telomerase reverse transcriptase (hTERT) [5] and prohibitin 2 [6] , thereby linking the enzyme with epigenetic regulation, aging and mitochondrial respiratory complex assembly respectively. SK1 and SK2 exhibit some redundancy in function, as evident from studies in Sphk1 -/-or Sphk2 -/-mice, which are phenotypically healthy while deletion of both genes is embryonic lethal [7] . These enzymes appear to regulate discrete sub-cellular pools of intracellular S1P that govern both overlapping and/or distinct biology. The importance of SK2 is evinced by the fact that it has a critical role in governing the clinical efficacy of FTY720 (Gilenya ® ), which is phosphorylated by SK2 to produce FTY720-phosphate and which functions to modulate S1P
receptors. SK1 and SK2 are regulated by post-translational modification and interact with specific proteins and lipids (for review see [8] ). For instance, both enzymes are phosphorylated by extracellular signal-regulated kinase (ERK) and this promotes translocation of SK1 from the cytoplasm to the plasma-membrane, where it can access sphingosine [9, 10] . In contrast, SK2 is localised to the endoplasmic reticulum, nucleus or is associated with mitochondria [11] . In addition, SK2 contains nuclear localisation and export sequences and when phosphorylated by protein kinase D is exported from the nucleus to the cytoplasm [12] . The aim of this opinion is to evaluate the role of SK2 in autoimmune/inflammatory disease. This is both necessary and timely because data obtained using Spk2 -/-mice suggest an anti-inflammatory role for this enzyme, while SK2 inhibitors indicate a pro-inflammatory role. It is important to appraise this issue so that the full potential of SK2 as a target for therapeutic intervention in autoimmune/inflammatory disease can be evaluated. We have therefore discussed the data obtained with Sphk2 -/-mice, assessed the role of SK2 in IL-12 signalling and Th17 polarisation that contribute to autoimmune disease and have provided information on how inhibitor selectivity for SK2 over SK1 inhibitors can be achieved. This is necessary to distinguish SK2 function from that of SK1 and to provide impetus for the use of SK2 inhibitors in autoimmune/inflammatory disease.
Consideration of evidence obtained with Sphk2 -/-mice
Data obtained using Sphk2 -/-mice suggest that SK2 might function as an antiinflammatory enzyme. In our opinion, the Sphk2 -/-model is not entirely informative as genetic knockout or RNAi knockdown of SK2 in cells can lead to increased expression of SK1 [13] [14] [15] .
In addition, Sphk2 -/-mice exhibit higher S1P levels in whole blood, serum, lymphatic fluid and mesenteric lymph nodes and it has been suggested that this is due to a compensatory increase in SK1 expression [16] . Other studies have shown no change in SK1 mRNA in brain, heart and lung, liver, spleen and kidney in Sphk2 -/-mice, although protein expression was not investigated [7] . Clearly, further studies are required to investigate the inter-relationship between SK2 and SK1. Nevertheless, the pro-inflammatory effects observed in Sphk2 -/-mice might be attributable to increased SK1 expression. Indeed, Sphk1 -/-mice are protected from ulcerative colitis, indicating that SK1 functions as a pro-inflammatory enzyme in this disease [17] . Such an increase in SK1 expression levels in the Sphk2 -/-mice is not recapitulated with selective SK2
inhibitors. These data indicate that there is a fundamental difference in how chronic loss of SK2 protein through genetic knockout/knockdown versus inhibition of SK2 activity with small molecules can affect SK1 expression. In our opinion, this has hindered evaluation as to whether SK2 is, in fact, a pro-inflammatory enzyme and therefore, a viable target for intervention in autoimmune/inflammatory disease. In addition, Kharel et al. [18] observed that the treatment of mice with the SK2 inhibitor, SRL080811 increased blood S1P levels. This contrasts with the effect of SK2 inhibitor, ABC294640 which lowers S1P levels [19] . Since SRL080811 recapitulated the effect of Sphk2 -/-mice, the authors have suggested that SK2 might exhibit additional activities in regulating S1P uptake into cells. However, the effects of SRL080811 and the Sphk2 knockout might represent mutually exclusive events. vitro. However, the authors suggested that these effects are independent of S1P and S1P
receptors. The former is based on the finding that intracellular S1P levels are not altered in Sphk2 -/-CD4 + cells. This is, in fact, consistent with increased SK1 expression rebalancing S1P levels and/or possible non-catalytic functions of SK2 affecting CD4 + cells; the latter which would not be recapitulated by SK2 inhibitors. Therefore, the observed effects of Sphk2 knockout on IL-2 signalling in these cells might be mediated by SK1.
Second, Bajwa et al. [21] demonstrated that Sphk2 -/-mice do not develop kidney fibrosis in response to injury induced by folic acid and that this is associated with increased levels of the pro-inflammatory mediator, IFN-, which is anti-fibrotic. Thus, SK2 is suggested to be a negative regulator of IFN-. However, an earlier publication by this group demonstrated that SK1 mRNA transcript levels are increased in SK2 null mice in kidneys subjected to ischaemic/reperfusion injury [22] . Moreover, overexpression of SK1 increases IL-12 formation from dendritic cells and RNAi knockdown in these cells prevents IFN- formation from Th1 cells [23] . Therefore, the effects on IFN- formation in Sphk2 -/-mice might be attributable to increased expression of SK1. A significant finding in the study by Bajwa et al. [21] was the demonstration that the number of infiltrating CD3 + T cells, CD11b + neutrophils and macrophages in the fibrotic kidney from Sphk2 -/-mice are considerably reduced compared with WT mice. This cannot be explained by an increase in SK1 expression in Sphk2 -/-mice, as this would potentially increase inflammatory cell infiltration in the kidney. Therefore, the antiinflammatory profile is likely attributable to the loss of SK2 and this supports our proposal that SK2 is, in fact, a pro-inflammatory enzyme that can affect T-cell dynamics. In addition, folic acid increased mRNA expression levels of innate pro-inflammatory mediators e.g. CXCL1 and CXCL2 in WT and Sphk1 -/-mice but not Sphk2 -/-mice.
There is more direct evidence obtained using Sphk2 -/-mice that SK2 can function in a pro-inflammatory context as these mice are protected against experimental auto-immune encephalomyelitis (EAE) [24] , a disease model of Multiple Sclerosis (MS). In addition, we have shown that the M potent SK2 inhibitor, (R)-FTY720 methyl ether (ROMe) prevents inflammatory cell infiltration into the spinal cord and recapitulates the Sphk2 knockout in reducing disease progression in the EAE model [25] . In addition, the SK2 inhibitor, Yeliva ® (ABC294640) exhibits anti-inflammatory activity in rodent models of Inflammatory Bowel Disease (IBD) [26] [27] [28] and arthritis [29] . Finally, hydroxy-based SK1/SK2 inhibitors have also been shown to exert anti-inflammatory activity in colitis in mice [30] . Therefore, there is some preliminary evidence that SK2 inhibitors might be exploited for the treatment of autoimmune/inflammatory disease.
Rationale for targeting sphingosine kinase 2
SK1 is involved in so-called 'inside-out' signalling, where S1P formed by SK1 is released from cells through transporters to act on S1P receptors in an autocrine manner [31] .
Evidence that SK2 can perform a similar function is scant. However, SK2 catalyses the phosphorylation of FTY720, and the phosphorylated FTY720 can be released from cells to functionally antagonise S1P 1 on T-cells [32] . Significantly, this underlies the mechanism by which FTY720 phosphate modulates T-cell polarisation and trafficking and which is clinically effective in MS patients. Therefore, SK2 can indirectly regulate S1P receptors and this is consistent with the partial redundancy of function seen in Sphk1 -/-or Sphk2 -/-mice. It follows that the selective inhibition of SK2 activity has the potential to block localized S1P synthesis, thereby reducing availability of S1P at S1P receptors and at intracellular targets (e.g. HDAC-1/2) involved in inflammatory disease-forming mechanisms ( Figure. 1 ). This is a plausible therapeutic approach as S1P is involved in IBD, Psoriasis (Ps) and MS [33, 34] .
Target validation of SK2 in Th1 driven auto-immune disease
Is there evidence that SK2 can function in molecular signalling pathways that affect Tcell sub-sets that drive auto-immune disease? In this regard, the IL121 receptor, which binds IL-12, has been shown to form a complex with SK2 [35] . Moreover, over-expression of dominant negative or wild-type SK2 reduce and enhance IL-12-stimulated IFN- formation respectively in T-cells ( Figure 2 ) [35] . Therefore, it would be of considerable interest to evaluate the effect of more potent SK2 inhibitors with selectivity over SK1 and in combination with for example, IL-12 antibodies to establish whether there is improved efficacy in Th1-mediated disease models compared with either agent alone ( Figure 3 ). In theory, decreasing IL-12 levels with antibody should reduce the extent to which SK2 can be activated by IL-12 and this might enable SK2 inhibitors to more effectively block IL-12-stimulated IFN- production.
SK2 and potential link with STAT3, IL-6 and IL-17
SK2 might also play a significant role in Th17 biology. This is based on the fact that the IL-23 receptor dimerizes with IL121 receptor required for IL-23-stimulated IL-17 formation [36] . Indeed, there is substantial evidence supporting a role for S1P in promoting Th17 polarisation [37] . For instance, S1P increases phosphorylated Signal Transducer Activator of Transcription 3 (STAT3) levels and IL-6 formation [38] ; the latter is a major stimulator of Th17 polarisation. In addition, STAT3 increases ROR-t expression [39] and STAT3 or ROR-t knockout reduces Th17 polarisation [39, 40] . Based on these findings, it is possible that S1P
stimulates Th17 polarisation via a ROR-t-dependent mechanism. Therefore, one could evaluate the effect of more potent SK2 inhibitors with selectivity over SK1 in combination with IL-17 antibodies to establish whether there is improved efficacy in Th17-mediated disease models compared with either agent alone ( Figure 3 ). SK2 inhibitors are expected to reduce IL-17 formation, thereby increasing the capacity for IL-17 antibody (at a given dose) to neutralise the lower amounts of IL-17 produced.
SK2 and potential link with T(reg) and auto-immune disease
S1P also inhibits T(reg) (Foxp3 + ) [41] and this involves an S1P 1 -dependent negative regulation of TGF signalling that requires SK activity and is blocked by SK inhibitors. Both SK1 and SK2 in T(reg) are up-regulated by TGF. However, SK1 normally promotes TGF signalling. For instance, SK1 is involved in TGF-stimulated fibroblast transformation mediated by S1P 2/3 [42] . Thus, TGF might alternatively use SK2 to increase S1P levels, which via 'inside-out' signalling acts on S1P 1 , thereby inhibiting TGF-induced T(reg) formation in a negative feedback manner. Thus, SK2 inhibitors might enhance T(reg) function to suppress autoimmune disease and this could be potentially augmented by combination with anti-IL-12 and IL-17 antibodies.
SK2 and potential link with ROR-t
HDAC-1 catalyses de-acetylation of ROR-t [43] and reduces its stability in cells.
Indeed, HDAC1 inhibitors maintain acetylated ROR-t to increase Th17 polarisation [43] .
Significantly, S1P formed by SK2 inhibits HDAC1 [44] . Thus, SK2 inhibitors, in reducing S1P levels might reactivate HDAC1 and promote ROR-t deacetylation and degradation, thereby limiting Th17 polarisation. This also provides a rationale for evaluating whether combined treatment with SK2 inhibitors and ROR-t inverse agonists improves efficacy in Th17-mediated disease models ( Figure. 3). In reducing ROR-t stability, SK2 inhibitors might enable inverse agonists to decrease ROR-t activity to below threshold levels required to promote IL-17 formation. Such threshold levels are likely to exist as weak strength T-cell activation is sufficient to stimulate IL-17 formation [45] .
Potential advantages of targeting SK2 over S1P receptors in auto-immune disease
A major effort in tackling auto-immune disease involves the use of S1P 1 modulators, such as Gilenya ® and ozanimod, which initially agonise S1P 1 and then promote proteasomal degradation of the receptor (functional antagonism) to prevent T-cell egress and therefore limit deleterious effects of autoreactive T-cells on the central nervous system (CNS). Side effects of certain S1P receptor modulators include transient bradycardia, QT prolongation, macular edema, early reduced FEV, headache, anaemia, higher transaminase levels (liver), nasopharyngitis, urinary tract and viral infection. SK2 inhibitors are not reliant on S1P 1/3 agonism thereby potentially minimising some of these side effects. Moreover, Yeliva ® causes only a modest decrease in lymphocyte count. This is important, as a severe decrease in lymphocytes number may make patients susceptible to certain infections including rare, but fatal progressive multifocal leukoencephalopathy (PML). Indeed, lymphopenia is linked with reactivation of the JC virus, which causes PML [46] . The modest effect of Yeliva ® on lymphocyte recirculation is supported by a partial or no effect on lymphopenia in Sphk2 -/-mice [24, 47] . Therefore, patients treated with SK2 inhibitors might have reduced risk from infection compared with the use of S1P 1 functional antagonists.
Selectivity of SK2 inhibitors over SK1
SK2-selective inhibitors reported to date include compounds 1-5 ( Figure. 4, [26, [48] [49] [50] Currently no SK2 crystal structures are available, but sequence comparison reveals strong homology to SK1, for which co-crystal structures with sphingosine (Sph) and with three Sphcompetitive inhibitors (6-8, Figure 4 ) have recently been solved [53] [54] [55] . Of the ca. 20 residues contributing to the ligand contact surface of the J-channel, SK2
differs from SK1 in only three; these are Ile174, Met272 and Phe288 of SK1, corresponding respectively to Val304, Leu517 and Cys533 in SK2. Ile174 and Met272 contribute to the stem of the J-channel. In the SK1 co-crystal structure with PF-543 (8) (Figure 5C ), these residues flank the inhibitor's p-xylylene subunit; their replacement by Val and Leu may result in some recontouring of SK2 J-channel surface in this region. Phe288 plugs the toe of the SK1 J-channel; the cognate residue (Cys533) in SK2 is likely to result in a longer J-channel. However, homology modelling suggests that isoform differences in non-contact residues may subtly adjust packing of LBLs and potentially impact on the conserved heel region of the J-channel, leading to some compaction in SK2 ( Figure 5D ).
Another non-contact residue difference that may have bearing on development of SK2-selective inhibitors is the substitution of Ala339 in SK1 by Thr584 in SK2. This residue lies proximal to a conserved aspartate (Asp178 in SK1) that engages the polar head group of Sph and inhibitors such as PF-543. Homology models indicate that presentation of the cognate aspartate (Asp308) in SK2 may be rotationally constrained by a hydrogen bond to Thr584 ( Figure 5E ).
This, in turn, may impact on the optimal binding position of a basic centre within a ligand head group. In the case of the hydroxymethylpyrrolidine subunit of PF-543, this would suggest a preference for a slightly more deeply seated ammonium centre when bound to SK2. The pronounced SK1-over-SK2 inhibitory selectivity of PF-543 may then result from a tendency for a modest backward shunt of the ligand tail to sub-optimally compress the sulfonylmethylene linker in the heel region of the J-channel, which we suggest is tighter in SK2 than SK1 due to compaction of LBL-3. Together these considerations suggest a strategy for the design of improved SK2 inhibitors by optimizing the ligand tail with softened steric demand in the heel and increased steric demand in the toe relative to SK1-selective inhibitors. Combining such a tail with a head group that doubly engages Asp308 (via OD1/OD2 oxygen centres) and spacer subunits of optimal length to bridge between the tail and head group may provide access to potent SK2 inhibitors with enhanced selectivity over SK1.
Finally, given the flap-like structure of the lipid binding loops, we should also consider protein flexibility and whether 'tunneling' of inhibitor tail subunits might be possible either between LBL-1/3 or between LBL-2/3. Thus, Schnute et al. [50] have recently disclosed Pfizer27c (5) as a potent SK2 inhibitor with modest selectivity over SK1. These authors note that direct mapping of Pfizer-27c onto SK1-bound PF-543 reveals that the terminal oxadiazole ring is too large for accommodation in the heel of the J-channel, and thus it is proposed that phenoxy ring is rotated to present the oxazdiazole between helices 8 and 9 of LBL-1 and LBL-3.
Validation of such a binding mode might open alternative strategies for optimizing SK2-selective inhibitors to take advantage of isoform differences in residues not directly contributing to the J-channel.
Concluding Remarks
One has to carefully de-convolute data obtained with Sphk2 
Figure Legends
Figure. 1 Effect of inhibiting SK2 on S1P-dependent autoimmune/inflammatory disease forming mechanisms. The schematic shows that inhibiting SK2 activity can potentially reduce the availability of S1P at S1P receptors, which regulates Th17 polarisation. In addition, S1P
formed by SK2 can bind to intracellular targets such as HDAC-1/2, which can regulate ROR-t (a master transcriptional regulator of Th17 polarisation) stability and suggesting that SK2
inhibitors might therefore reduce ROR-t levels. 
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